Respiratory Distress in The Newborn
Respiratory Distress in The Newborn
Respiratory Distress in The Newborn
EPIDEMIOLOGY 1
RISK FACTORS FOR RESPIRATORY DISTRESS 2
SIGNS OF RESPIRATORY DISTRESS 2
PATHOGENESIS 2
O EARLY GESTATION 2
O LATE GESTATION 2
O POST-NATAL 2
DIFFERENTIAL DIAGNOSIS OF RESPIRATORY DISTRESS 3
AIRWAY CAUSES 3
PULMONARY CAUSES 3
CARDIOVASCULAR CAUSES 3
THORACIC CAUSES 3
NEUROMUSCULAR CAUSES 3
MISCELLANEOUS 3
TRANSIENT TACHYPNEA OF THE NEWBORN 3
O RISK FACTORS 3
O PRESENTATION 3
O CXR 4
O MANAGEMENT 4
NEONATAL PNEUMONIA 4
O RISK FACTORS 4
O PRESENTATION 4
O CXR 4
O MANAGEMENT 4
O COMPLICATION 4
RESPIRATORY DISTRESS SYNDROME 5
O RISK FACTORS 5
O PRESENTATION 5
O MANAGEMENT 5
MECONIUM ASPIRATION SYNDROME 5
O RISK FACTORS 5
O MANAGEMENT 6
O COMPLICATION 6
Epidemiology
o 15% in term infants
o 29% in late preterm
Pathogenesis
o The type of disease depends on the stage of development it occurred at & if it is pre or post-
natal
o Early Gestation (0 to 16 weeks):
▪ Tracheoesophageal Fistula
▪ Bronchopulmonary sequestration: abnormal mass of pulmonary tissue not connected to
the tracheobronchial tree
▪ Bronchogenic cysts: abnormal branching of the tracheobronchial tree
o Late Gestation (17 to 36 weeks): parenchymal lung malformations
▪ Congenital cystic adenomatoid malformation
▪ Pulmonary hypoplasia from congenital diaphragmatic hernia or severe oligohydramnios,
o Post-Natal:
▪ Transient Tachypnea of the Newborn (TTN)
▪ Respiratory Distress Syndrome (RDS)
▪ Neonatal Pneumonia
▪ Meconium Aspiration Syndrome (MAS)
o Management: Supportive
▪ Supplement oxygen ± CPAP
▪ Blood Gas: mild respiratory acidosis & hypoxemia
o Self-limiting course of disease
Neonatal Pneumonia
o MC form: Perinatal pneumonia
▪ Acquired at birth
o MC Organism: Group B Streptococcus
o Risk Factors:
▪ Prolonged Rupture of Membranes (PROM)
▪ Chorioamnionitis / Maternal Infection
▪ Prematurity
o Presentation: increased work of breathing + oxygen requirement
o CXR:
▪ Diffuse parenchymal infiltrates with
air bronchograms
▪ Lobar consolidation
o Management:
▪ Supplemental oxygen + CPAP ± HFOV
▪ Replacement with exogenous surfactant
o Complication: pneumomediastinum, pneumothorax, and PPHN